Business
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
CAMBRIDGE, Mass., December 09, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/3dc32a03bd7799bc9e38ec279ca689f4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I1df9zCylstYQSNPOZwz5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3dc32a03bd7799bc9e38ec279ca689f4","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XgivdxwJrqT7BfA7cygoEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/3dc32a03bd7799bc9e38ec279ca689f4","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Once issued, this new U.S. Patent will expand the scope of Enveric’s EVM301 patent portfolio of potential neuroplastogenic molecules for treatment of neuropsychiatric conditions.","length":178,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., December 09, 2025--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.","length":543,"tagName":"p"},{"type":"text","content":"The USPTO issues a Notice of Allowance after making the determination that a patent should be granted from an application.","length":122,"tagName":"p"},{"type":"text","content":"Entitled, "N-heterocycle substituted tryptamine derivatives and methods of using," the application will add to the portfolio of patents issued for Enveric’s EVM301 Series of molecules. The compositions claims and methods of use claims covered by this patent will further broaden Enveric’s pipeline by covering additional potential neuroplastogenic non-hallucinogenic molecules and strengthening its potential to target neuropsychiatric and addiction disorders for patients with few other options.","length":506,"tagName":"p"},{"type":"text","content":""We continue to work diligently to ...